SGLT2 Inhibitors Treatment Market Analysis

Application (Glucose Dissipation, Blood Transfusion)

The glucose dissipation segment is estimated to hold 56% share of the global SGLT2 inhibitors treatment market during the forecasted timeframe. Due to the advancement in glucose dissipation, the SGLT2 treatment market is addressed the unbeatable growth of 8.6% over the years. In order to decrease high blood glucose, the SGLT2 inhibitors work by a new mechanism to reduce renal tubular glucose reabsorption and thus decrease blood glucose levels without inducing the release of insulin.

End Users (Hospitals, Clinics, Diagnostic Centers)

SGLT2 inhibitors treatment market from the diagnostic centers sector is predicted to show the largest share of 42 % by the end of 2037. The qualified healthcare professionals in diagnostic centers with a growing estimation of 14% per annum, such as endocrinologists or primary care physicians, often diagnose and prescribe SGLT2 inhibitors after thoroughly evaluating a patient's medical history, present health, and needs for diabetic management. Moreover, the rising investment in diagnostic services is further expected to boost the segment’s growth. For instance the National Health Service, spends more than USD 6 billion on more than 90 diagnostic services in a year.

Our in-depth analysis of the global market includes the following segments: